Novartis Friday announced results from a head-to-head trial of its secukinumab (Cosentyx) versus adalimumab in patients with active psoriatic arthritis (PsA), saying its therapy missed statistical significance for its primary end point.
Novartis Friday announced results from a head-to-head trial of its secukinumab (Cosentyx) versus adalimumab in patients with active psoriatic arthritis (PsA), saying its therapy missed statistical significance for its primary end point.
The interleukin-17 (IL-17) inhibitor is already approved to treat ankylosing spondylitis, PsA, and plaque psoriasis.
Although secukinumab missed showing superiority for American College of Rheumatology criteria for 20% improvement (ACR20) at week 52, the company said it showed numerical superiority.
In the EXCEED trial comparing secukinumab to adalimumab, PsA-specific end points were seen in a pre-specified sensitivity analysis. No new safety signals were detected, with results showing a consistent and favorable safety profile for secukinumab, similar to previous trials.
EXCEED, the first double-blinded head-to-head clinical trial evaluating secukinumab at a dose of 300 mg versus adalimumab at a dose of 40 mg, is a 52-week, multicenter, randomized, double-blind, active control, Phase 3b trial evaluating the efficacy of secukinumab compared with adalimumab in over 800 patients with active PsA who are naïve to biologics.
Secukinumab was administered at baseline, weeks 1-4, and then every 4 weeks until week 48. Adalimumab 40 mg was administered at baseline, and then every 2 weeks until week 50.
Secukinumab has less frequent dosing than adalimumab, which won’t face biosimilar competition until 2023, although other therapies, such as oral agents as well as other injectable competitors are waiting in line.
“These data will be welcomed by patients and clinicians to guide clinical decision making and highlight secukinumab as a viable option as a first-line biologic for the treatment of psoriatic arthritis,” says Iain McInnes, a professor of rheumatology at the University of Glasgow and an investigator in the secukinumab clinical trial program.
“EXCEED is the first ever monotherapy head-to-head trial with a primary end point in psoriatic arthritis specific to joints.” said Eric Hughes, global development unit head, Immunology, Hepatology & Dermatology. “We will assess the EXCEED data in their totality and we view the results as confirming our vision of Cosentyx becoming standard of care in psoriatic arthritis.”
Detailed data will be presented at a future scientific congress.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.